DAT in the context of chemotherapy is an acronym that means a chemotherapy regimen most often used as an induction regimen in acute myelogenous leukemia, usually for those who are refractory to the standard "7+3" induction regimen or who has relapsed. But this regimen also can be used as primary, first-line induction therapy.
The DAT regimen consists of:
- (D)aunorubicin - an anthracycline antibiotic that is able to intercalate DNA, thus disrupting cell division and preventing mitosis;
- (A)ra-C (cytarabine) - an antimetabolite;
- (T)hioguanine - another antimetabolite.
|Ara-C (cytarabine)||200 mg/m2||IV push every 12 hours in 2 divided doses (100 mg/m2 each)||Days 1-10|
|Daunorubicin||50 mg/m2||IV slow push||Days 1, 3 and 5|
|Thioguanine||200 mg/m2||PO every 12 hours in 2 divided doses (100 mg/m2 each)||Days 1-10|